8-KLeadership ChangesRegulation FDOther Events+1

QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Apr 11, 2012)

Filed April 11, 2012For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on April 11, 2012, announcing significant changes in its executive leadership and Board of Directors. Effective April 30, 2012, Dr. Surya N. Mohapatra will step down from his roles as Chairman of the Board, President, and CEO, and also resign from the Board. This departure is in accordance with a letter agreement dated October 21, 2011. Concurrently, the Board elected Stephen H. Rusckowski as the new President and CEO, effective May 1, 2012. Mr. Rusckowski brings extensive experience from Royal Philips Electronics, where he served as CEO of Philips Healthcare. He will also join the Board of Directors. Additionally, Daniel C. Stanzione, Ph.D., will assume the role of non-executive Chairman of the Board, effective May 1, 2012, succeeding Dr. Mohapatra in that capacity.

Key Highlights

  • 1Dr. Surya N. Mohapatra is departing from his roles as Chairman, President, and CEO of Quest Diagnostics, effective April 30, 2012.
  • 2Stephen H. Rusckowski has been appointed as the new President and CEO, effective May 1, 2012, and will also join the Board of Directors.
  • 3Mr. Rusckowski's compensation package includes a base salary of $1,050,000, with significant equity awards totaling approximately $10 million on his commencement date, including stock options, performance shares, and restricted stock units.
  • 4A lump-sum cash payment of $500,000 and 20,000 restricted stock units are being provided to Mr. Rusckowski as a sign-on inducement and to compensate for prior employment forfeitures.
  • 5Dr. Daniel C. Stanzione will transition to the role of non-executive Chairman of the Board, effective May 1, 2012.
  • 6Dr. Stanzione will receive additional compensation for his new role, including a $72,500 cash retainer and $72,500 in non-qualified stock options.
  • 7The filing details employment terms, including a target incentive compensation of 130% of base salary for Mr. Rusckowski and various benefit programs.

Frequently Asked Questions

The 8-K filing indicates that Dr. Surya N. Mohapatra's departure as Chairman, President, and CEO is in accordance with a prior letter agreement dated October 21, 2011. While the exact reasons for the agreement are not detailed in this filing, it signifies a planned leadership transition.

Mr. Rusckowski's compensation includes an annual base salary of $1,050,000. He is eligible for annual incentive compensation with a target of 130% of his base salary, with a guaranteed minimum of $1,365,000 for 2012. He will also receive substantial equity awards upon commencement, including stock options, performance shares, and restricted stock units, with a target value of approximately $10 million, plus additional sign-on awards and a $500,000 cash payment.

Dr. Daniel C. Stanzione, who is currently the Lead Independent Director, will be appointed as the non-executive Chairman of the Board, effective May 1, 2012. He will continue his role on the Board's Governance Committee and will receive additional compensation for these duties.

Yes, Mr. Rusckowski is required to refund the $500,000 'Make Whole Cash Payment' if he voluntarily terminates his employment without 'Good Reason' or if the Company terminates his employment for 'Cause' before the first anniversary of his commencement date. The Make Whole Restricted Stock Units also have specific vesting conditions and potential forfeiture clauses.